Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.39 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.39 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 3/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6482379 | 0.90 | CTPS1 (0.43) | CYSLTR2CYSLTR1CTPS1GPR119PPARA | |
| SCHEMBL6474127 | 0.88 | CYSLTR2 (0.43) | CYSLTR2CYSLTR1CTPS1PPARAMAPT | |
| SCHEMBL6473587 | 0.87 | TP53 (0.45) | PPARAMAPTPPARGTP53POLB | |
| SCHEMBL6475724 | 0.86 | TP53 (0.42) | CYSLTR2CYSLTR1CTPS1GPR119PPARA | |
| SCHEMBL6474743 | 0.85 | TP53 (0.44) | MAPTTP53LMNA | |
| SCHEMBL6483737 | 0.85 | SHMT2 (0.46) | CYSLTR2CYSLTR1CTPS1PPARAMAPT | |
| SCHEMBL6479428 | 0.85 | PPARA (0.41) | CYSLTR2CYSLTR1CTPS1PPARAMAPT | |
| SCHEMBL6474952 | 0.84 | PPARG (0.41) | CYSLTR2CYSLTR1CTPS1MAPTPPARG | |
| SCHEMBL6474761 | 0.81 | CYSLTR2 (0.39) | CYSLTR2CYSLTR1CTPS1PPARAMAPT | |
| SCHEMBL6477804 | 0.81 | CYSLTR2 (0.42) | CYSLTR2CYSLTR1CTPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6930131-B2 | Aryl substituted 3-ethoxy phenyl trifluoromethane sulfonamides for the treatment of non-insulin dependent diabetes mellitus (NIDDM) | WYETH (US) | 2005-08-16 | — | — | US | disclosed |
| US-20030203941-A1 | Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus | WYETH (US) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203941-A1 | Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus | GPR119, INSR, SLC5A1 | CYSLTR2 4703/4885CYSLTR1 4632/4885CTPS1 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.